Athira Pharma

Athira Pharma is a clinical stage American biopharmaceutical company developing regenerative therapies for neurological diseases such as Alzheimer's disease and Parkinson's disease. The company was founded in 2011 and is headquartered in Seattle, USA.
Athira Pharma stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Athira Pharma balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Athira Pharma cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Athira Pharma multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Athira Pharma profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Athira Pharma assets
Athira Pharma cash flows

Athira Pharma dividend policy

The company doesn't provide dividend

Athira Pharma shares

TickerNameTypeNominal valueISINPrice
ATHA:USAthira PharmaCommon share-US04746L1044$0.6509
Athira Pharma news
13.05.2022
Athira Pharma's GAAP loss for 3 months of 2022 was $20.98 million, up 2.37 times from $8.866 million in the previous year.
Source: {source} pictogram investors.athira.com
Pictogram next
25.03.2022
Athira Pharma's GAAP loss for 2021 was $54.853 million, up 2.8 times from $19.955 million in the previous year.
Source: {source} pictogram investors.athira.com
Pictogram next
11.11.2021
Athira Pharma's GAAP loss for 9M 2021 was $38.514 million, up 3.2 times from $12.253 million in the previous year.
Source: {source} pictogram investors.athira.com
Pictogram next
17.08.2021
Athira Pharma's GAAP loss for 6M 2021 was $22.84 million, a six-fold increase from $3.797 million in the previous year.
Source: {source} pictogram investors.athira.com
Pictogram next
All Athira Pharma news
General information
Company nameAthira Pharma
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address4000 Mason Road Suite 300, PO Box 352141 Seattle, WA 98195 United States
Mailing address4000 Mason Road Suite 300, PO Box 352141 Seattle, WA 98195 United States
Websiteinvestors.athira.com
Information disclosurewww.sec.gov